Songs for soprano, alto, tenor and bass: Op. 41, 48, 59, 88, 100.

Mode of access: Internet.

Die englischen Marineausgaben und deren Deckung seit 1887-88.

Thesis (doctoral)--Ludwig-Maximilians-Universitat Munchen.

Proposed Gulf of Alaska/Cook Inlet lease sale 88 : final environmental impact statement /

Item 603-G

Galleria biografica della Nuova rivista degli scacchi : (estratti dalle annate 1885-86-87-88).

"Ritratti e biografie di G.M. Borgi, G. Moreno, G.B. Maluta, C.B. Vansittart, L. Sprega, V. Salimbeni."

Fragm. lat. II 88 - Breviarium (Sonn- und Ferialtage nach Pfingsten)

Trägerbände: Inc. qu. 781; Inc. qu. 1106; Inc. oct. 387; Inc. oct. 395; Vorbesitzer: Dominikanerkloster Frankfurt am Main

Fragm. lat. I 80 - Psalterium (Ps 67,31 - 36; 68,1 - 4; 73,10 - 23; 88,8 - 25)

Trägerband: Inc. fol. 237; Vorbesitzer: Bartholomaeusstift Frankfurt am Main

Fragm. lat. I 88 - Missale (Sabb. a.Dom.passionis; Dom.; Fer.III p.Dom.passionis)

Trägerband: Inc. qu. 1011

Handbüchlein zur angenehmen und nützlichen Beschäftigung für junge Damen, oder Encyclopädie der vorzüglichsten weiblichen Kunstarbeiten, namentlich des Zuschneidens und Nähens der Wäsche ... ; mit 88 Abbildungen

von Charlotte L***

Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88)

The phosphosulfomannan 1 (PI-88) is a mixture of highly sulfated oligosaccharides that is currently undergoing clinical evaluation in cancer patients. As well as it's anticancer properties, 1 displays a number of other interesting biological activities. A series of analogues of 1 were synthesized with a single carbon (pentasaccharide) backbone to facilitate structural characterization and interpretation of biological results. In a fashion similar to 1, all compounds were able to inhibit heparanase and to bind tightly to the proangiogenic growth factors FGF-1, FGF-2, and VEGF. The compounds also inhibited the infection of cells and cell-to-cell spread of herpes simplex virus (HSV-1). Preliminary pharmacokinetic data indicated that the compounds displayed different pharmacokinetic behavior compared with 1. Of particular note was the n-octyl derivative, which was cleared 3 times less rapidly than 1 and may provide increased systemic exposure.

A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors

Purpose: PI-88 is a mixture of highly sulfated oligosaccharides that inhibits heparanase, an extracellular matrix endoglycosidase, and the binding of angiogenic growth factors to heparan sulfate. This agent showed potent inhibition of placental blood vessel angiogenesis as well as growth inhibition in multiple xenograft models, thus forming the basis for this study. Experimental Design: This study evaluated the toxicity and pharmacokinetics of PI-88 (80-315 mg) when administered s.c. daily for 4 consecutive days bimonthly (part 1) or weekly (part 2). Results: Forty-two patients [median age, 53 years (range, 19-78 years); median performance status, 1] with a range of advanced solid tumors received a total of 232 courses. The maximum tolerated dose was 250 mg/d. Dose-limiting toxicity consisted of thrombocytopenia and pulmonary embolism. Other toxicity was generally mild and included prolongation of the activated partial thromboplastin time and injection site echymosis. The pharmacokinetics were linear with dose. Intrapatient variability was low and interpatient variability was moderate. Both AUC and C-max correlated with the percent increase in activated partial thromboplastin time, showing that this pharmacodynamic end point can be used as a surrogate for drug exposure, No association between PI-88 administration and vascular endothelial growth factor or basic fibroblast growth factor levels was observed. One patient with melanoma had a partial response, which was maintained for >50 months, and 9 patients had stable disease for >= 6 months. Conclusion: The recommended dose of PI-88 administered for 4 consecutive days bimonthly or weekly is 250 mg/d. PI-88 was generally well tolerated. Evidence of efficacy in melanoma supports further evaluation of PI-88 in phase II trials.